Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients with Major Depressive Disorder

Trial Profile

Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients with Major Depressive Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Vortioxetine (Primary) ; Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 05 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2017 This trial has been completed in Estonia (end date: 2017-04-27), according to European Clinical Trials Database.
    • 26 May 2017 This trial was completed in Finland (end date: 2017-04-27), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top